US paediatric panel to review adverse events for four proton pump inhibitors
This article was originally published in Scrip
Executive Summary
The US FDA's paediatric advisory committee will meet on 21 June to discuss paediatric-focused safety reviews for 13 drugs, including four proton pump inhibitors.